Prospect Capital Corporation
PSEC-PA
New York Stock Exchange16.68
USD
-0.04
- -
Prospect Capital Corporation
PSEC-PA
(New York Stock Exchange)
Recent
price
16.68
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Prospect Capital Corporation (NASDAQ: PSEC-PA) operates as a leading publicly-traded business development company that provides flexible private debt and equity financing to middle-market companies in the United States and Canada. The company specializes in first-lien and second-lien senior secured loans, often with equity-linked investments, to support refinancings, leveraged buyouts, acquisitions, recapitalizations, later-stage growth capital, and capital expenditures; its diversified portfolio spans industries including healthcare providers and services, consumer finance, commercial services and supplies, distributors, logistics, software, food, and multi-family real estate. Prospect Capital targets sponsor-owned and non-sponsor-owned businesses, emphasizing senior and secured lending to generate current income and long-term capital appreciation for shareholders. Founded in 2004 following its initial public offering and headquartered at 10 East 40th Street, 44th Floor, New York, New York, the company manages over $7.0 billion in assets across more than 400 investments funded, with locations throughout the U.S. Prospect Capital's customers primarily include private equity sponsors and established middle-market firms seeking capital for strategic growth and operational needs. In recent developments, Prospect Capital completed the acquisition of QC Holdings, Inc., a provider of consumer-focused alternative financial services including short-term loans through brands like LendNation, in an all-cash transaction valued at approximately $115 million on June 30, 2025. During its fiscal year ended June 30, 2024, the company closed $764 million in new investments across 38 portfolio companies, with 91% comprising first-lien senior secured loans, including significant financings such as $56 million to a clinical trial services provider, $60 million to a business process outsourcing firm, and $26 million to a healthcare detox and rehabilitation provider. Prospect Capital also received recognition in the 2025 Middle-Market Deals of the Year Awards for its value-added convertible term loan to Druid City Infusion, supporting expansion in the home infusion therapy sector.